Zenith Electronics is a century-old U.S. technology company now operating as LG Electronics' U.S. research subsidiary. Its legacy includes major consumer-electronics and broadcast innovations (remote controls, FM stereo, HDTV transmission techniques) and it now focuses on technology development and licensing—most notably Pro:Idiom DRM for the hospitality market—while continuing work in consumer, broadcasting, mobile DTV and emergency alert technologies, supported by public heritage materials and corporate contacts.

Zepbound (tirzepatide) is a potent once‑weekly dual GIP/GLP‑1 agonist for chronic weight management that produces substantial, dose‑dependent weight loss and glycemic benefits when combined with diet and exercise. Initiation uses a stepwise titration to reduce gastrointestinal adverse effects; common side effects are GI‑related while rarer but serious risks (pancreatitis, gallbladder disease, acute kidney injury, and a rodent thyroid C‑cell tumor signal) require pre‑treatment evaluation and ongoing monitoring. It interacts with drugs whose absorption or glucose‑lowering effects may be altered (notably insulin, sulfonylureas, and possibly combined oral contraceptives during titration). Formulations include prefilled pens and vials with refrigeration requirements. Access and cost depend on insurance, prior authorization, and program options; combining medication with behavioral, nutritional, and follow‑up support yields better outcomes.